Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · IEX Real-Time Price · USD
0.277
+0.009 (3.36%)
At close: Apr 25, 2024, 4:00 PM
0.273
-0.004 (-1.52%)
After-hours: Apr 25, 2024, 7:24 PM EDT
Company Description
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States.
It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name.
The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.
The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Mangoceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Mar 21, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jacob D. Cohen |
Contact Details
Address: 15110 Dallas Pkwy, Suite 600 Dallas, Texas 75248 United States | |
| Phone | (833) 626-4679 |
| Website | mangorx.com |
Stock Details
| Ticker Symbol | MGRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001938046 |
| ISIN Number | US56270V1061 |
| Employer ID | 87-3841292 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Jacob D. Cohen | Chief Executive Officer and Chairman |
| Eugene M. Johnston | Chief Financial Officer |
| Amanda Elizabeth Hammer | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 8-K | Current Report |
| Apr 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 1, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 23, 2024 | 8-K | Current Report |
| Jan 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |